Mark Bloomfield

Back small companies to deliver new medicines

Pharmaceutical R&D functions at its best in small, agile and innovative SMEs. Replacing state subsidies and grant funding for research with start-up and development capital, would bring productivity improvements, says Mark Bloomfield, CEO of French biotech Polyplus Transfection